Oklo Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

OKLO INC : NYSE - LinkedIn

📈 Stoneblack Equity Research initiates coverage with a 'Speculative Buy' rating and a 12-month price target of USD 78, implying ~89.9% upside from the current price of USD 41.09.

🏗️ Oklo received DOE Documented Safety Analysis approval on July 1, 2026, and startup authorization on July 23, 2026, for its Groves Isotope Test Reactor with first criticality targeted this month.

💰 The company completed a USD 1.5 billion at-the-market equity program in January 2026, raising net proceeds of USD 1.182 billion to fund its capital-intensive project pipeline.

🤝 Meta has executed a prepayment agreement supporting the development of a 1.2 GW Aurora power campus in Southern Ohio, with Phase 1 targeting 150 MW around 2030.

⚠️ Oklo missed the original Executive Order deadline for criticality by three weeks (July 4 vs. July 23) without explicit public acknowledgment of the slippage.

📉 The stock has declined approximately 79% from its January 2026 high of USD 193.80 to a current price of USD 41.09, trading near its 52-week low of USD 36.63.

🔬 Oklo remains entirely pre-revenue with Q4 2025 revenue at USD 0.00 and reported EPS of negative USD 0.19 for the last quarter.

🚀 The Aurora-INL commercial powerhouse is under construction at Idaho National Laboratory, targeting commercial power delivery by late 2027.

🧬 Oklo's Atomic Alchemy subsidiary provides a parallel isotope production business using fast-spectrum plutonium criticality experiments and fuel recycling technology.

📊 The company employs 205 people in Santa Clara, California, operating an asset-light, technology-and-licensing-focused model.

🏆 Oklo pursues a multi-pathway regulatory strategy utilizing both the NRC combined license process and the DOE Reactor Pilot Program authority.

📉 Barclays lowered its price target to USD 76 while maintaining a Buy rating, whereas Guggenheim initiated with a Hold rating and a USD 54.06 target.

Bullish Signals
  • Oklo received critical regulatory approvals from the DOE on July 1 and July 23, 2026, clearing the path for fuel loading and first criticality of the Groves reactor.
  • The company secured a USD 1.5 billion equity raise in January 2026, providing substantial operating runway to fund construction projects before the subsequent share price decline.
  • Oklo has established binding relationships with credible institutional counterparties including Meta, the Department of Energy, and Idaho National Laboratory.
  • The company's multi-pathway regulatory strategy provides parallel authorization tracks, reducing dependence on a single regulatory timeline or risk profile.
  • Oklo's balance sheet was meaningfully strengthened through the January 2026 capital raise, reducing near-term dependence on further dilutive fundraising at depressed prices.
  • CEO Jacob DeWitte has led the company through accelerated regulatory execution, achieving startup authorization in just over 10 months from groundbreaking.
Risk Factors
  • Oklo missed the original Executive Order deadline for criticality by three weeks (July 4 vs. July 23) without explicit public acknowledgment of the timeline slippage.
  • The Meta agreement is structured as a prepayment with Phase 1 deployment targeting only 150 MW around 2030, which is considerably smaller than the headline 1.2 GW figure often cited.
  • Oklo remains entirely pre-revenue with Q4 2025 revenue of USD 0.00 and a full fiscal year 2024 net loss of USD 73.62 million.
  • Competitors Antares Nuclear and Valar Atomics achieved initial criticality within the same DOE programme ahead of Oklo, complicating its narrative as the sector leader.
  • The company's stock has fallen approximately 79% from its January 2026 high, trading near its 52-week low with a confirmed technical sell signal.
  • Federal loan program allocation is tilting toward large reactors rather than the small modular and microreactor category Oklo operates within.
Full Analysis
Stoneblack Equity Research initiates coverage on Oklo Inc. (NYSE: OKLO) with a 'Speculative Buy' rating and a 12-month price target of USD 78, implying approximately 89.9% upside from the current price of USD 41.09. The report highlights a significant disconnect between the company's accelerating operational milestones and its collapsing stock price, which has fallen roughly 79% from its January 2026 high despite receiving key regulatory approvals. Oklo, formerly AltC Acquisition Corp., is developing fast fission power plants with its flagship Aurora reactor design. The company recently received Department of Energy Documented Safety Analysis approval and startup authorization for its Groves Isotope Test Reactor on July 1 and July 23, 2026, respectively, clearing the path for first criticality targeted for the current month. However, the stock hit a fresh 52-week low of USD 36.63 during this window, trading near its floor. The investment thesis relies on Oklo's multi-pathway regulatory strategy, binding relationships with Meta and the Department of Energy, and the approaching binary catalyst of the Groves reactor's first criticality. While the company remains pre-revenue with a market cap of approximately USD 7 billion, it has strengthened its balance sheet via a USD 1.5 billion equity program completed in January 2026, providing operating runway despite shareholder dilution. The report identifies specific risks including Oklo missing the original Executive Order deadline for criticality by three weeks without public acknowledgment, and the Meta agreement being more modest (150 MW by 2030) than headline figures suggest. Analysts note that while competitors like Antares Nuclear achieved criticality earlier in the same program, Oklo's verified regulatory execution and institutional validation offer a differentiated entry point for risk-tolerant investors.